Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B.
BACKGROUND
Lipoprotein-X (Lp-X) is an abnormal lipoprotein found in the plasma of patients with familial lecithin:cholesterol acyltransferase (LCAT) deficiency. The majority of patients with this disorder develop progressive glomerulosclerosis. One key event in the pathogenesis of glomerulosclerosis is the infiltration of monocytes into affected glomeruli. Mesangial cells can synthesize and secrete monocyte chemoattractant protein-1 (MCP-1), an important chemoattractant for monocytes. The objective of the present study was to examine the effect of Lp-X on MCP-1 expression in mesangial cells leading to an enhanced monocyte chemotaxis and to elucidate the mechanisms involved in this process.


METHODS
Lp-X was isolated from the plasma of a patient with familial LCAT deficiency. After rat mesangial cells were incubated with Lp-X for four or six hours, the expression of MCP-1 mRNA was determined by nuclease protection assay, and MCP-1 protein was measured by Western immunoblotting analysis. Monocyte chemotaxis was determined by using a Micro Chemotaxis Chamber.


RESULTS
Lp-X (50 to 100 nmol/mL) stimulated mesangial cell MCP-1 mRNA expression (137 to 220%) and MCP-1 protein levels (233 to 375%). Conditioned media collected from Lp-X-treated mesangial cells stimulated human acute monocytic leukemia (THP-1) monocyte chemotaxis (165 to 200%). The increase in MCP-1 expression in mesangial cells was associated with an elevation of intracellular diacylglycerol levels, and activation of protein kinase C (PKC) as well as nuclear factor-kappa B (NF-kappa B).


CONCLUSIONS
These results suggest that Lp-X participates in the pathogenesis of glomerulosclerosis and subsequent renal failure in familial LCAT deficient patients by stimulating monocyte infiltration via a mechanism involving mesangial MCP-1 expression.
Lynn
E G
EG
Department of Pharmacology, Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
Siow
Y L
YL
Frohlich
J
J
Cheung
G T
GT
O
K
K
D000595:Amino Acid Sequence; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000235:genetics* / Q000378:metabolism; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology; D002784:Cholesterol / Q000378:metabolism; D004075:Diglycerides / Q000378:metabolism; D004110:Diltiazem / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005487:Foam Cells / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects / Q000276:immunology; D005808:Genes, Recessive; D005920:Glomerular Mesangium / Q000166:cytology / Q000378:metabolism*; D005923:Glomerulosclerosis, Focal Segmental / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007863:Lecithin Cholesterol Acyltransferase Deficiency / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D008073:Lipoprotein-X / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D008969:Molecular Sequence Data; D009000:Monocytes / Q000166:cytology; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010713:Phosphatidylcholines / Q000378:metabolism; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D019311:Staurosporine / Q000494:pharmacology; D010738:Type C Phospholipases / Q000378:metabolism
D002121:Calcium Channel Blockers; D018932:Chemokine CCL2; D004075:Diglycerides; D004791:Enzyme Inhibitors; D007211:Indoles; D008073:Lipoprotein-X; D016328:NF-kappa B; D010713:Phosphatidylcholines; D011758:Pyrroles; D012333:RNA, Messenger; C085989:Ro 32-0432; D002784:Cholesterol; D011493:Protein Kinase C; D010738:Type C Phospholipases; D004110:Diltiazem; D019311:Staurosporine